Neodjuvant Chemoimmunotherapy Takes Another Step Forward in Stage IIIA-B NSCLC

(MedPage Today) -- VIENNA -- The addition of neoadjuvant nivolumab (Opdivo) to chemotherapy significantly improved outcomes in patients with resectable stage IIIA-B non-small cell lung cancer, according to results from the NADIM II trial. The...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news